Johnson & Johnson (JNJ) Q4 2024 Annual Earnings
Johnson & Johnson reported Q4 2024 revenue of $22.5B, beat analyst consensus of $22.4B by $88.8M. Diluted EPS came in at $2.04, beat the $1.99 consensus by $0.05. Johnson & Johnson reports across 2 business segments, led by Innovative Medicine and MedTech.
Financial Snapshot
Trailing eight quarters through Q4 2024
Q4 2024 Earnings FAQ
Common questions about Johnson & Johnson's Q4 2024 earnings report.
Johnson & Johnson (JNJ) reported Q4 2024 earnings on January 22, 2025 before market open.
Johnson & Johnson reported revenue of $22.5B and diluted EPS of $2.04 for Q4 2024.
Revenue beat the consensus estimate of $22.4B by $88.8M. EPS beat the consensus estimate of $1.99 by $0.05.
You can read the 8-K/A earnings release (0000200406-25-000007) and the 10-K periodic report (0000200406-25-000038) directly on SEC EDGAR. The filing index links above go to sec.gov.